Research
Hormonal
Pharmacotherapy is recommended for postmenopausal females and males aged 50+ who have had a previous hip or vertebral fracture, or have a 10-year major osteoporotic fracture risk of 20% or more.
If you are over 50 and have had a hip or vertebral fracture, or have a high 10-year fracture risk (20% or more), you should strongly consider pharmacotherapy. This is a strong recommendation based on high-certainty evidence. Your doctor will help you choose the right medication based on your specific risks and preferences.
StrongSupportsHIGH confidence
We recommend initiating pharmacotherapy in postmenopausal females and males aged ≥ 50 yr who a. have had previous hip, vertebra or ≥ 2 osteoporosis-related fractures OR b. have a 10-yr major osteoporotic fracture risk ≥ 20% OR c. are aged ≥ 70 yr and have a T-score ≤ –2.5.
Why this rating
Strong recommendation with high-certainty evidence for females.
Source
Clinical practice guideline for management of osteoporosis and fracture prevention in Canada: 2023 update
Suzanne N. Morin et al. · Canadian Medical Association Journal · 2023
clinical_guidelineCited 180×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →